VEGFA and neoplasm: In contrast, in the syngeneic RENCA model, MP0250 showed stronger anti-tumor activity than the VEGFR inhibiting kinase inhibitor sorafenib, implicating a more critical role for HGF than VEGF in the growth of these tumors.